دورية أكاديمية
Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study
| العنوان: | Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study |
|---|---|
| المؤلفون: | Galasso S., Facchinetti A., Bonora B. M., Mariano V., Boscari F., Cipponeri E., Maran A., Avogaro A., Fadini G. P., Bruttomesso D. |
| المساهمون: | Galasso, S., Facchinetti, A., Bonora, B. M., Mariano, V., Boscari, F., Cipponeri, E., Maran, A., Avogaro, A., Fadini, G. P., Bruttomesso, D. |
| بيانات النشر: | Elsevier B.V. |
| سنة النشر: | 2016 |
| المجموعة: | Padua Research Archive (IRIS - Università degli Studi di Padova) |
| مصطلحات موضوعية: | Basal-bolus therapy, Glycaemic control, Insulin degludec, Type 1 diabete, Adult, Biomarker, Blood Glucose, Circadian Rhythm, Diabetes Mellitus, Type 1, Drug Administration Schedule, Female, Human, Hypoglycemia, Hypoglycemic Agent, Insulin Detemir, Insulin Glargine, Insulin, Long-Acting, Italy, Male, Middle Aged, Patient Satisfaction, Prospective Studie, Risk Factor, Time Factor, Treatment Outcome, Young Adult, Drug Substitution |
| الوصف: | Background and aims Degludec is an ultralong-acting insulin analogue with a flat and reproducible pharmacodynamic profile. As some patients with type 1 diabetes (T1D) fail to achieve 24-h coverage with glargine or detemir despite twice-daily injections, we studied the effect of switching T1D patients from twice-daily glargine or detemir to degludec. Methods and Results In this prospective observational study, T1D patients on twice-daily glargine or detemir were enrolled. At baseline and 12 weeks after switching to degludec, we recorded HbA1c, insulin dose, 30-day blood glucose self monitoring (SMBG) or 14-day continuous glucose monitoring (CGM), treatment satisfaction (DTSQ), fear of hypoglycemia (FHS). We included 29 patients (mean age 34 ± 11 years; diabetes duration 18 ± 10 years). After switching to degludec, HbA1c decreased from 7.9 ± 0.6% (63 ± 6 mmol/mol) to 7.7 ± 0.6% (61 ± 6 mmol/mol; p = 0.028). SMBG showed significant reductions in the percent and number of blood glucose values <70 mg/dl and in the low blood glucose index (LBGI) during nighttime. CGM showed a significant reduction of time spent in hypoglycemia, an increase in daytime spent in target 70–180 mg/dl, and a reduction in glucose variability. Total insulin dose declined by 17% (p < 0.001), with 24% reduction in basal and 10% reduction in prandial insulin. DTSQ and FHS significantly improved. Conclusion Switching from twice-daily glargine or detemir to once daily degludec improved HbA1c, glucose profile, hypoglycemia risk and treatment satisfaction, while insulin doses decreased. ClinicalTrials.gov NCT02360254. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/27618501; info:eu-repo/semantics/altIdentifier/wos/WOS:000389518200008; volume:26; issue:12; firstpage:1112; lastpage:1119; numberofpages:8; journal:NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES; http://hdl.handle.net/11577/3343951Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84994804587 |
| DOI: | 10.1016/j.numecd.2016.08.002 |
| الإتاحة: | https://doi.org/10.1016/j.numecd.2016.08.002Test http://hdl.handle.net/11577/3343951Test |
| رقم الانضمام: | edsbas.67133D63 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.numecd.2016.08.002 |
|---|